---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-26-000094"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2026-10-20T12:36:27+00:00"
generated_at: "2026-10-20T12:40:06.191437+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics to sell prenatal health testing business to Labcorp for $210 million cash

## Summary
- Myriad Genetics agreed to sell its Prenatal Health testing business, including Prequel, Foresight, SneakPeek and FirstGene, to Labcorp for $210 million cash plus closing inventory value.
- Labcorp expects the acquisition to add about $160 million in revenue in year one, be slightly accretive to adjusted earnings in year one, and reach diagnostics segment margins by end of year two.
- The deal is subject to HSR and state health care approvals and is expected to close by early 2027; either party may terminate if not closed by Feb. 19, 2027, with extension to Oct. 19, 2027.
- Labcorp would pay Myriad a $10.5 million termination fee if the agreement is terminated due to failure to obtain certain regulatory clearances.

## SEC filing metadata
- accession: 0000899923-26-000094
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2026-10-20T12:36:27+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992326000094/0000899923-26-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992326000094/mygn-20261019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-26-000094
- JSON: https://secwatch.observer/filing/0000899923-26-000094.json
- Plain text: https://secwatch.observer/filing/0000899923-26-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.